- Home
- Life Sciences
- Biotechnology
- Biopharmaceutical
- World Enzymes Industry
World Enzymes Industry
- Publication date: December 2011
- Report price: $ 6 100
Get this report today!
Summary
Table of Contents
World enzyme demand to reach $7.6 billion by 2015
With most countries having begun the process of recovering from the global financial crisis of 2009, world enzyme demand will rise at a healthy pace to reach $7.6 billion in 2015. Almost all markets will experience average annual growth rates in excess of five percent, with the exception of biofuel production and a few other small industrial enzyme markets. Reflecting the broad-based nature of the growth, demand will be strong for all enzyme types, especially smaller product categories. From a regional perspective, the fastest increases will be in the smaller markets of Central and South America, and the Africa/Mideast region. The Asia/Pacific region will also undergo a rapid increase in enzyme demand due to strength in China and India. A moderating trend in the developed economies of North America and Western Europe will lead to healthy, though below average growth. In particular, North American enzyme demand will suffer from a slow transition to biomass-based biofuel production, while enzyme consumption in Western Europe will be held back by the impact of the European debt crisis.
Animal feed, food & beverage markets to lead gains
Through 2015 world enzyme demand will average annual increases of 6.3 percent, led by animal feed and food and beverage enzymes, which will both benefit from the expansion of the middle class in rapidly developing economies. Diagnostics enzyme demand will also fare well due to expanded access to medical care in developing countries, and the advent of health care reform in the United States. With pharmaceutical companies having difficulty bringing new small-molecule drugs to market, biotechnology will continue to gain in importance, helping to sustain demand for research and biotechnology enzymes and drive robust growth in biocatalyst enzyme demand. Among the other industrial enzyme markets, cleaning products will realize the strongest growth as new enzymes continue to be launched in developed countries, and greater market penetration is achieved in developing countries. Biofuel production enzyme demand, however, will moderate significantly. While the increased use of enzymes in biodiesel and sugar cane-based ethanol production will support growth, the lack of new legislative mandates for grainbased ethanol will limit increases in the near term. While the development of second generation biofuels derived from cellulosic raw materials will help sustain demand growth over the long term, a variety of processes -- including some that do not use enzymes -- will be employed, restraining advances. Growth in the various other industrial markets will be below average going forward as market maturity in areas such as textile and starch enzymes limits gains.
Smaller-volume enzymes to grow the fastest
In terms of the enzyme types, the fastest growth will be in smaller volume enzymes such as phytases and some specialty pharmaceutical enzymes for treating lysosomal storage disorders. Polymerases and nucleases will also have above-average growth due to the strength of the diagnostic and the research and biotechnology markets. Lipases will be just above average, while proteases and carbohydrases will trail the other types reflecting their greater use in established industrial enzyme markets.
Study coverage
This new Freedonia industry study, World Enzymes, presents historical demand data (2000, 2005, 2010) plus forecasts (2015, 2020) by product, market, world region and for 16 major countries. The study also assesses market environment factors, evaluates company market shares and profiles 33 industry players such as Allergan, DSM, DuPont, Roche, Novozymes and Sanofi-Aventis.
Global Biopharmaceutical Industry
- Publication date: December 2011
- Report price: $ 6 100
Get this report today!
Talk to Robyn
(866) 682 9815
Search ReportLinker
The Largest Collection of Market Research Reports
» 450,000 Company Profiles
» 40,000 Country Guides
From +200,000 authoritative sources
Global Biopharmaceutical Industry : Latest Reports
Analytical Tool - Antibodies and Peptides in Oncology
- $ 8 925
- Industry report
- April 2013
- by Bioseeker
"Analytical Tool - Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and ...
![Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017](https://d99ngkg9mjpdb.cloudfront.net/public/images/pub/1329.gif)
Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017
- $ 4 650
- Industry report
- March 2013
- by MarketsandMarkets
Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently ...
Triple Analysis: Cancer Vaccines, Antibodies and Peptides
- $ 5 175
- Industry report
- March 2013
- by Bioseeker
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Cancer Vaccines and by the two compound strategies of Antibodies and Peptides. Each of these three individual ...
More Reports:
Biopharmaceutical in China (12)
Global Biopharmaceutical Industry : Latest Downloads
Enzyme Sector Analysis
- Industry report
- March 2013
- 90 pages
... Production Preparation of enzymes 21/03/2013 why enzymes Catalysts increase the rate of reactions without any net change in their structure. Concept of catalysis is developed as early as the 19th ...
Biopharmaceutical Industry Brief
- Industry report
- October 2012
- 8 pages
... Alfa was non-inferior to imiglucerase if the lower limit of the one-sided 97.5% Confidence interval (ci) of the treatment difference (velaglucerase alfa minus imiglucerase) was greater than -1 g ...
Biopharmaceutical Sector Brief
- Industry report
- October 2012
- 6 pages
... E in upstream and downstream development. As an example of pharmaceutical proteins whole production processes of potential malaria vaccines are investigated in detail. In the field of technical enzymes ...
World Biopharmaceutical Industry Overview
8 months agoAntibody Market Brief
8 months agoBiopharmaceutical : Innovation And Technology ...
8 months agoBiopharmaceutical Market Brief
9 months agoBiosimilar Sector Brief
9 months agoBioprocessing Business Brief
9 months agoBiopharmaceutical Sector Brief
10 months agoMore Reports:
Biopharmaceutical in Australia (8)
Company Reports
ref:plp2011
Reportlinker.com © Copyright 2013. All rights reserved.
